Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives

Classical BCR-ABL-negative myeloproliferative neoplasms (MPN) are a heterogeneous group of hematologic malignancies, including essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF), as well as post-PV-MF and post-ET-MF. Progression to more symptomatic disease, such...

Full description

Bibliographic Details
Published in:	Cells
Main Authors:	Julian Baumeister, Nicolas Chatain, Alexandros Marios Sofias, Twan Lammers, Steffen Koschmieder
Format:	Article
Language:	English
Published:	MDPI AG 2021-12-01
Subjects:	MPN progression diagnosis therapy
Online Access:	https://www.mdpi.com/2073-4409/10/12/3551

Similar Items

Myeloproliferative Neoplasm Symptom Assessment Total Symptom Score (MPN-SAF TSS) in Chronic Myeloproliferative Neoplasms with Relation to Genetic Burden and Thrombosis
by: Elif Gülsüm Ümit, et al.
Published: (2024-09-01)

Clinical characteristics and symptom burden of Thai myeloproliferative neoplasm patients
by: Naritsara Cherdchoo, et al.
Published: (2023-12-01)

The Approach to Thrombosis Prevention across the Spectrum of Philadelphia-Negative Classic Myeloproliferative Neoplasms
by: Steffen Koschmieder
Published: (2021-06-01)

Is There a Role for Direct Oral Anticoagulants in the Primary and Secondary Prevention of Myeloproliferative Neoplasm Associated Thrombosis?
by: Uzma Faruqi, et al.
Published: (2021-12-01)

Impact of mutations on pregnancy outcome in patients with myeloproliferative neoplasms
by: Dawn Maze, et al.
Published: (2023-02-01)

Not just for mature audiences: myeloproliferative neoplasms in children, adolescents, and young adults
by: Linda Resar, et al.
Published: (2025-05-01)

Myelodysplastic/Myeloproliferative Neoplasms with Features Intermediate between Primary Myelofibrosis and Chronic Myelomonocytic Leukemia: Case Series and Review of the Entity
by: Arturo Bonometti, et al.
Published: (2024-07-01)

MPN: The Molecular Drivers of Disease Initiation, Progression and Transformation and their Effect on Treatment
by: Julian Grabek, et al.
Published: (2020-08-01)

Disabled, invisible and dismissed—The lived experience of fatigue in people with myeloproliferative neoplasms
by: Ashleigh Bradford, et al.
Published: (2023-01-01)

Inflammation and anti-inflammatory approaches in myeloproliferative neoplasm
by: Steffen Koschmieder, et al.
Published: (2018-06-01)

The clinical relevance of broad mutational screening of myeloproliferative neoplasms at diagnosis
by: Helna Pettersson, et al.
Published: (2023-08-01)

JAK2-positive Philadelphia-negative myeloproliferative neoplasms
by: Anjali Sharma, et al.
Published: (2011-01-01)

Novel Therapies in Myeloproliferative Neoplasms: Beyond JAK Inhibitor Monotherapy
by: Sophia S. Lee, et al.
Published: (2021-08-01)

Diagnostic and Therapeutic Challenges of Chronic Portal Vein Thrombosis Secondary to Myeloproliferative Neoplasm in Sub-Saharan Region: A Series of Cases and Literature Review
by: Mohammed A, et al.
Published: (2023-01-01)

MicroMPN: methods and software for high-throughput screening of microbe suppression in mixed populations
by: Karla Franco Meléndez, et al.
Published: (2024-03-01)

Mutations, inflammation and phenotype of myeloproliferative neoplasms
by: Sylvie Hermouet, et al.
Published: (2023-05-01)

Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms
by: Michael J. Hochman, et al.
Published: (2021-08-01)

Clinical characteristics and management of headache in patients with myeloproliferative neoplasms
by: Takashi Shimoyama, et al.
Published: (2022-12-01)

The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling
by: Kathrin Olschok, et al.
Published: (2023-10-01)

Pediatric Philadelphia-Negative Myeloproliferative Neoplasms in the Era of WHO Classification: A Systematic Review
by: Abdulrahman F. Al-Mashdali, et al.
Published: (2023-01-01)

IL-4 Serum Level Estimation in Myeloproliferative Neoplasm Patients
by: Ahmed Rushdi Abdullah
Published: (2022-04-01)

Clinical Discernment, Bone Marrow, and Molecular Diagnostics Are Equally Important to Solve the Phenotypic Mimicry among Subtypes of Myeloproliferative Neoplasms
by: Susann Schulze, et al.
Published: (2021-08-01)

Comparison of PCR with Standard Method (MPN) for detection of bacterial contamination in drinking water
by: Fatemeh Dehghan, et al.
Published: (2014-11-01)

The effects of mutational profiles on phenotypic presentation of myeloproliferative neoplasm subtypes in Bosnia: 18 year follow-up
by: Amina Kurtovic-Kozaric, et al.
Published: (2020-05-01)

Philadelphia-Negative MPN: A Molecular Journey, from Hematopoietic Stem Cell to Clinical Features
by: Valentina Giai, et al.
Published: (2021-09-01)

Differential modulation of mutant CALR and JAK2 V617F-driven oncogenesis by HLA genotype in myeloproliferative neoplasms
by: Velizar Shivarov, et al.
Published: (2024-09-01)

Detection of Escherichia coli Contamination using Most Probable Number (MPN) methods in Chicken Meats in Market of Surabaya
by: Dhandy Koesoemo Wardhana, et al.
Published: (2021-04-01)

MPN-RRT*: A New Method in 3D Urban Path Planning for UAV Integrating Deep Learning and Sampling Optimization
by: Yue Zheng, et al.
Published: (2025-07-01)

P988: MUTANT CALRETICULIN AND JAK2V617F DRIVER MUTATIONS INDUCE DISTINCT MITOTIC DEFECTS IN MYELOPROLIFERATIVE NEOPLASMS
by: Kristin Holl, et al.
Published: (2023-08-01)

P984: MUTATIONAL PATTERNS IN PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (MPN)
by: I. C. Casetti, et al.
Published: (2022-06-01)

A novel truncated fusion gene ETV6::AC010198.2 in post-MPN acute myeloid leukemia caused by del(12)(p13p11)
by: Jiao Lu, et al.
Published: (2025-02-01)

Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms
by: Kristin Holl, et al.
Published: (2024-02-01)

Adrenal infarction with latent myelodysplastic/myeloproliferative neoplasm, unclassifiable with JAK2V617F mutation
by: Shunichiro Yasuda, et al.
Published: (2024-04-01)

Mathematical modelling of stem and progenitor cell dynamics during ruxolitinib treatment of patients with myeloproliferative neoplasms
by: Tobias Idor Boklund, et al.
Published: (2024-05-01)

Patients With Myeloproliferative Neoplasms Harbor High Frequencies of CD8 T Cell-Platelet Aggregates Associated With T Cell Suppression
by: Ana Micaela Carnaz Simões, et al.
Published: (2022-05-01)

Corrigendum: Patients with myeloproliferative neoplasms harbor high frequencies of CD8 T cell-platelet aggregates associated with T cell suppression
by: Ana Micaela Carnaz Simões, et al.
Published: (2022-08-01)

Prevalence and clinicopathological features of driver gene mutations profile in BCR:ABL1 negative classical myeloproliferative neoplasm—A single-center study from North India
by: Khaliqur Rahman, et al.
Published: (2024-12-01)

Elevated Vitamin B12 Levels in Myeloproliferative Neoplasm (MPN) Patients: A Potential Diagnostic and Prognostic Marker
by: Fadul A, et al.
Published: (2024-12-01)

Evaluation of the Effect of <italic>NQO1 C609T (rs1800566)</italic> Gene Variations in Philadelphia-negative Myeloproliferative Neoplasms in Turkish Population
by: Ayşegül Başak Akadam Teker, et al.
Published: (2020-01-01)

Mitigation of atrial fibrillation‐related complications with antithrombotic and cytoreductive therapy in patients with Myeloproliferative Neoplasms: Implications from the GSG‐MPN bioregistry
by: Hyunyee Rosa Cho, et al.
Published: (2025-03-01)